Apellis' Empaveli Poised To Give Soliris A Run In PNH
New Drug Reaches The Market With Broad Label And Competitive Pricing
The first targeted C3 therapy was approved by the US FDA for treatment-naïve patients as well as those switching from Alexion's Soliris or Ultomiris.
You may also be interested in...
NGM said a Merck-partnered C3 inhibiting antibody has failed a Phase II study in geographic atrophy, after the biotech’s wholly owned NASH candidate missed in a Phase IIb study in 2021.
The company plans to file the complement C5 inhibitor with the US FDA, but Apellis already has a drug pending for the indication.
One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.